Market Cap | 72M | P/E | 9.88 | EPS this Y | - | Ern Qtrly Grth | - |
Income | -61.96M | Forward P/E | 1.27 | EPS next Y | - | 50D Avg Chg | -14.00% |
Sales | 355.55M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -48.00% |
Dividend | N/A | Price/Book | EPS next 5Y | - | 52W High Chg | -76.00% | |
Recommedations | 2.00 | Quick Ratio | 1.34 | Shares Outstanding | 45.57M | 52W Low Chg | 5.00% |
Insider Own | 35.80% | ROA | -2.93% | Shares Float | 28.92M | Beta | - |
Inst Own | 10.92% | ROE | -12.99% | Shares Shorted/Prior | 56.19K/105.64K | Price | 1.58 |
Gross Margin | 30.54% | Profit Margin | -17.43% | Avg. Volume | 46,562 | Target Price | 33.76 |
Oper. Margin | -35.85% | Earnings Date | Apr 1 | Volume | 17,168 | Change | 1.28% |
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.